Abterra Bio is enabling the next-generation of antibody therapeutics. Our technologies use the latest in next-generation sequencing, mass spectrometry, and machine learning methods to comprehensively map the antibody response to challenge. We give our partners access to every relevant antibody to meet their project goals. Abterra Bio began life as Digital Proteomics LLC, a spin-out of the University of California – San Diego. Founders Pavel Pevzner and Vineet Bafna are professors in the Computer Science and Engineering Department and leading researchers in bioinformatics. Their expertise forms the algorithmic foundation upon which our products and services are built.